Skip to main content
SpringerLink
Log in

Efficient photodynamic therapy against drug-resistant prostate cancer using replication-deficient virus particles and talaporfin sodium

  • Original Article
  • Published:
Lasers in Medical Science Aims and scope Submit manuscript

A Correction to this article was published on 13 July 2020

This article has been updated

Abstract

To enhance the potency of photosensitizer, we developed a novel photosensitizer, Laserphyrin®-HVJ-E (L-HVJ-E), by incorporating talaporfin sodium (Laserphyrin®, Meiji Seika Pharma) into hemagglutinating virus of Japan envelope (HVJ-E). In this study, we examined the optimal Laserphyrin® concentration for preparation of Laserphyrin®-HVJ-E which had photocytotoxicity and maintained direct cytotoxicity derived from HVJ-E. Then, potency of Laserphyrin®-HVJ-E and Laserphyrin® were compared in vitro using castration-resistant prostate cancer cell line (PC-3). A laser diode (L660P120, Thorlabs, USA) with a wavelength of 664 nm was used for light activation of Laserphyrin®, which corresponds to an absorption peak of Laserphyrin® and provides a high therapeutic efficiency. The photocytotoxicity and direct cytotoxicity of Laserphyrin®-HVJ-E prepared using various Laserphyrin® concentrations were evaluated using PC-3 cell in vitro. We categorized the treatment groups as Group 1: 50 μL of D-MEM treatment group, Group 2: HVJ-E treatment group, Group 3: Laserphyrin®-HVJ-E treatment group, and Group 4: Laserphyrin® treatment group. Group 3 was subjected to different concentrations of Laserphyrin®-HVJ-E suspension, and all groups were subjected to different incubation periods (24, 48 h), (30 min, 1 h, or 3 h,) respectively, without and after PDT. Laserphyrin®-HVJ-E prepared using 15 mM Laserphyrin® had high photocytotoxicity and maintained HVJ-E’s ability to induce direct cytotoxicity. Therapeutic effect of Laserphyrin®-HVJ-E was substantially equivalent to that of Laserphyrin® alone even at half Laserphyrin® concentration. By utilizing Laserphyrin®-HVJ-E, PDT could be performed with lower Laserphyrin® concentration. In addition, Laserphyrin®-HVJ-E showed higher potency than Laserphyrin® by combining cytotoxicities of HVJ-E and PDT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Change history

References

  1. Ferlay J et al (Mar. 2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386

    Article  CAS  Google Scholar 

  2. Zhou CK et al (Mar. 2016) Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer 138(6):1388–1400

    Article  CAS  Google Scholar 

  3. Survival rates for prostate cancer. [Online]. Available: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html. [Accessed: 26-Dec-2019]

  4. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Liao Persson J (2012) Overcoming drug resistance and treating advanced prostate Cancer. Curr Drug Targets 13(10):1308–1323

    Article  CAS  Google Scholar 

  5. Juarranz Á, Jaén P, Sanz-Rodríguez F, Cuevas J, González S (2008) Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 10(3):148–154

    Article  CAS  Google Scholar 

  6. Allison RR, Sibata CH (2010) Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis and Photodynamic Therapy 7(2):61–75

    Article  CAS  Google Scholar 

  7. Anand S, Ortel BJ, Pereira SP, Hasan T, Maytin EV (2012) Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Letters 326(1):8–16

    Article  CAS  Google Scholar 

  8. Dougherty TJ, Cooper MT, Mang TS (Jan. 1990) Cutaneous phototoxic occurrences in patients receiving Photofrin®. Lasers Surg Med 10(5):485–488

    Article  CAS  Google Scholar 

  9. Agostinis P et al (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61(4):250–281

    Article  Google Scholar 

  10. Kataoka H et al (2017) New photodynamic therapy with next-generation photosensitizers. Annals of Translational Medicine 5(8) AME Publishing Company

  11. J. Akimoto, Photodynamic therapy for malignant brain tumors, Neurologia Medico-Chirurgica, vol. 56, no. 4. Japan Neurosurgical Society, pp. 151–157, 15-Apr-2016

  12. Usuda J et al (Dec. 2007) Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy. Lung Cancer 58(3):317–323

    Article  Google Scholar 

  13. Yano T et al (2017) A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget 8(13):22135–22144

    Article  Google Scholar 

  14. Wang S, Bromley E, Xu L, Chen JC, Keltner L (2010) Talaporfin sodium. Expert Opinion on Pharmacotherapy 11(1):133–140

    Article  CAS  Google Scholar 

  15. J. S. Nelson, W. G. Roberts, and M. W. Berns, In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy., undefined, 1987

  16. Minamide T et al (Feb. 2020) Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Surg Endosc 34(2):899–906

    Article  Google Scholar 

  17. Kaneda Y et al (2002) Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 6(2):219–226

    Article  CAS  Google Scholar 

  18. Zhang Q, Li Y, Shi Y, Zhang Y (2008) HVJ envelope vector, a versatile delivery system: Its development, application, and perspectives. Biochemical and Biophysical Research Communications 373(3) Academic Press:345–349

    Article  CAS  Google Scholar 

  19. Kaneda Y (2010) Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv 7(9):1079–1093

    Article  CAS  Google Scholar 

  20. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y (2009) Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 124(10):2478–2487

    Article  CAS  Google Scholar 

  21. Chang CY, Tai JA, Li S, Nishikawa T, Kaneda Y (2016) Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity. Oncotarget 7(27):42195–42207

    Article  Google Scholar 

  22. Matsushima-Miyagi T et al (2012) TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 18(22):6271–6283

    Article  CAS  Google Scholar 

  23. Hong Y et al (2018) Highly selective photodynamic therapy with a short drug-light interval using a cytotoxic photosensitizer porphyrus envelope for drug-resistant prostate cancer cells. Int J Clin Med 09(01):8–22

    Article  CAS  Google Scholar 

  24. Inai M et al (2017) Photodynamic therapy using a cytotoxic photosensitizer porphyrus envelope that targets the cell membrane. Photodiagn Photodyn Ther 20:238–245

    Article  CAS  Google Scholar 

  25. Akter S et al (2019) Photodynamic therapy by lysosomal-targeted drug delivery using talaporfin sodium incorporated into inactivated virus particles. LASER Ther

  26. Spikes JD, Bommer JC (1993) Photosensitizing properties of mono-l-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors. J Photochem Photobiol B Biol 17(2):135–143

    Article  CAS  Google Scholar 

  27. Matveeva OV, Kochneva GV, Netesov SV, Onikienko SB, Chumakov PM Mechanisms of oncolysis by Paramyxovirus Sendai. Acta Naturae 7(2):6–16

  28. Bateman A et al (2000) Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 60(6):1492–1497

    CAS  PubMed  Google Scholar 

  29. Ebert O, Shinozaki K, Kournioti C, Park MS, García-Sastre A, Woo SLC (2004) Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 64(9):3265–3270

    Article  CAS  Google Scholar 

  30. Saga K, Kaneda Y (2015) Oncolytic Sendai virus-based virotherapy for cancer: recent advances. Oncolytic virotherapy 4:141–147

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Kaneda Y (2013) The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis. Oncoimmunology 2(4)

Download references

Funding

This work was supported by Japan Society for the Promotion of Science KAKENHI Grant Number JP15K16322 and Japan Agency for Medical Research and Development (Project No. J169013067).

Author information

Authors and Affiliations

  1. Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Sharmin Akter, Sachiko Saito, Norihiro Honda, Hisanao Hazama & Kunio Awazu

  2. Department of Physiology, Bangladesh Agricultural University, Mymensingh, 2202, Bangladesh

    Sharmin Akter

  3. Graduate School of Frontier Biosciences, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Mizuho Inai & Kunio Awazu

  4. Institute for Academic Initiatives, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Norihiro Honda

  5. Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Tomoyuki Nishikawa & Yasufumi Kaneda

  6. Global Center for Medical Engineering and Informatics, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Kunio Awazu

Authors
  1. Sharmin Akter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sachiko Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mizuho Inai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norihiro Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hisanao Hazama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoyuki Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasufumi Kaneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kunio Awazu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharmin Akter.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akter, S., Saito, S., Inai, M. et al. Efficient photodynamic therapy against drug-resistant prostate cancer using replication-deficient virus particles and talaporfin sodium. Lasers Med Sci 36, 743–750 (2021). https://doi.org/10.1007/s10103-020-03076-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10103-020-03076-1

Keywords

Search

Navigation